© 2004, the authors Evidenced-based Complementary and Alternative Medicine, Vol. 1, Issue 3 © Oxford University Press 2004; all rights reserved. The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated.
Lecture Series |
Evidence-based Reconstruction of Kampo Medicine: Part-III—How Should Kampo be Evaluated?
Toyama Medical and Pharmaceutical University Japan
| The first 150 words of the full text of this article appear below. |
 |
Introduction |
|---|
In the previous two lectures, I tried to explain in detail that the paradigm of Kampo is basically different from that of modern Western medicine, focusing especially on the concept of Sho. Kampo has been developed to cope with Sho, not with the disease entities understood in terms of modern Western medicine. Thus, there is little point asking, for example, ‘Are there any Kampo remedies effective for lung cancer (or type C hepatitis, or essential hypertension)?’
This question, asked wrongly, however, highlights two important issues, one intriguing and long term, and the other important and short term. The former is that the effects of Kampo herbs have so far not been tested properly against any of the specific disease entities defined in the framework of modern Western medicine. The latter is that we urgently need some methods to accommodate evaluation of the clinical effects of Kampo remedies in the framework
|
Kampo as a Frontier of Research on Complex Agents (drugs): a Long-term View |
|---|
|
Evaluation of Kampo Formulae on Disease Entities in the Modern Western Framework: Standard and Novel Clinical Trials |
|---|
Standard Double-blind Randomized Control Trials (RCTs)
A Modified Double-blind RCT Based on Sho
New Trial Designs Being Investigated
For reprints and all correspondence: Professor Katsutoshi Terasawa, Department of Japanese-Oriental (Kampo) Medicine, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Japan. E-mail: terasawa@ms.toyama.ac.jp
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Kiefer, J. Pitluk, and K. Klunk An Overview of CAM: Components and Clinical Uses Nutr Clin Pract, October 1, 2009; 24(5): 549 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Oikawa, G. Ito, T. Hoshino, H. Koyama, and T. Hanawa Hangekobokuto (Banxia-houpo-tang), a Kampo Medicine that Treats Functional Dyspepsia Evid. Based Complement. Altern. Med., September 1, 2009; 6(3): 375 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Matsumoto, T. Kojima, K. Ogawa, S. Kamegai, T. Oyama, Y. Shibagaki, T. Kawasaki, H. Fujinaga, K. Takahashi, H. Hikiami, et al. A Proteomic Approach for the Diagnosis of 'Oketsu' (blood stasis), a Pathophysiologic Concept of Japanese Traditional (Kampo) Medicine Evid. Based Complement. Altern. Med., December 1, 2008; 5(4): 463 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Shijie, J. Moriya, J. Yamakawa, R. Chen, T. Takahashi, H. Sumino, T. Nakahashi, K. Iwai, S. Morimoto, N. Yamaguchi, et al. Mao-to Prolongs the Survival of and Reduces TNF-{alpha} Expression in Mice with Viral Myocarditis Evid. Based Complement. Altern. Med., February 24, 2008; (2008) nen010v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nozaki, H. Hikiami, H. Goto, T. Nakagawa, N. Shibahara, and Y. Shimada Keishibukuryogan (Gui-Zhi-Fu-Ling-Wan), a Kampo Formula, Decreases Disease Activity and Soluble Vascular Adhesion Molecule-1 in Patients with Rheumatoid Arthritis Evid. Based Complement. Altern. Med., September 1, 2006; 3(3): 359 - 364. [Abstract] [Full Text] [PDF]
|
|